PLUS1
Best deals to access real time data! |
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
DDE w/Realtime (Monthly)
Monthly Subscription
for only
|
|
Big Cap Pro
Monthly Subscription
for only
|
|
VAT not included
|
|
After Hours Last Trade |
Last $ 3.87 ▲ 0.10 (2.52%) | |
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Sorrento Therapeutics Inc | SRNE | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| -0.035 | -0.92% | 3.775 | 4.04 | 3.61 | 3.85 | 3.81 | 23:59:39 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 3.75 | 3.94 | 0.19 | 4.82% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 25,032 | 9,656,917 | $ 3.83 | $ 37,030,164 | 6,784,554 | 1.39 - 6.50 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:59:35 | formt | 100 | $ 3.87 | USD |
Sorrento Therapeutics Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 621.11M | 164.53M | $ -203.54M | -1.91 | - | 60.08M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | 63.50% |
Sorrento Therapeutics News
| Date | Time | Source | News Article |
|---|---|---|---|
| 12/09/2019 | 07:01 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 12/09/2019 | 07:00 | GlobeNewswire Inc. | Sorrento Announces New Board Member |
| 11/25/2019 | 07:01 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 11/25/2019 | 07:00 | GlobeNewswire Inc. | Sorrento Therapeutics, Inc. Received and Rejected.. |
| 11/13/2019 | 16:43 | Edgar (US Regulatory) | Confidential Treatment Order (ct Order) |
| 11/12/2019 | 07:05 | GlobeNewswire Inc. | Sorrento CEO to Present at Upcoming Investor Conferences |
| 11/12/2019 | 06:07 | Edgar (US Regulatory) | Quarterly Report (10-q) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SRNE Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 3.42 | 4.04 | 3.10 | 3.62 | 12,101,391 | 0.355 | 10.38% |
| 1 Month | 1.67 | 4.04 | 1.45 | 3.20 | 10,684,117 | 2.11 | 126.05% |
| 3 Months | 2.42 | 4.04 | 1.39 | 2.83 | 4,490,918 | 1.36 | 55.99% |
| 6 Months | 2.97 | 4.17 | 1.39 | 2.80 | 2,585,940 | 0.805 | 27.1% |
| 1 Year | 3.00 | 6.50 | 1.39 | 3.15 | 2,340,964 | 0.775 | 25.83% |
| 3 Years | 5.35 | 10.65 | 1.39 | 4.28 | 1,798,010 | -1.58 | -29.44% |
| 5 Years | 4.47 | 26.80 | 1.39 | 5.13 | 1,233,932 | -0.695 | -15.55% |
Sorrento Therapeutics Description
| Sorrento Therapeutics Inc is a biotechnology company focused on the development of novel immunotherapies for oncology and autoimmune/inflammation diseases. The antibody technologies target various locations: extracellular, intracellular, and membrane-bound antigens. The product portfolio consists of BioSimilar/BioBetter antibodies, CAR-T programs for treatment of solid tumors, adoptive cellular therapies, immuno-oncology mAbs, and antibody drug conjugates. |
